Population Pharmacokinetics and Pharmacodynamics of Mitomycin During Intraoperative Hyperthermic Intraperitoneal Chemotherapy
- 112 Downloads
Background: During recent years, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin has been used for various malignancies.
Objective: To characterise the population pharmacokinetics and pharmacodynamics of mitomycin during HIPEC.
Methods: Forty-seven patients received mitomycin 35 mg/m2 intraperitoneally as a perfusion over 90 minutes. Mitomycin concentrations were determined in both the peritoneal perfusate and plasma. The observed concentration-time profiles were used to develop a population pharmacokinetic model using nonlinear mixed-effect modelling (NONMEM). The area under the plasma concentration-time curve (AUC) was related to the haematological toxicity.
Results: Concentration-time profiles of mitomycin in perfusate and plasma were adequately described with one- and two-compartment models, respectively. The average volume of distribution of the perfusate compartment (V1) and rate constant from the perfusate to the systemic circulation (k12) were 4.5 ± 1.1L and 0.014 ± 0.003 min-1, respectively (mean ± SD, n = 47). The average volume of distribution of the central plasma compartment (V2), clearance from the central compartment (CL) and volume of distribution of the peripheral plasma compartment (V3) were 28 ± 16L, 0.55 ± 0.18 L/min and 36 ± 8L, respectively. The relationship between the AUC in plasma and degree of leucopenia was described with a sigmoidal maximum-effect (Emax) model.
Conclusion: The pharmacokinetics of mitomycin during HIPEC could be fitted successfully to a multicompartment model. Relationships between plasma exposure and haematological toxicity were quantified. The developed pharmacokinetic-pharmacodynamic model can be used to simulate different dosage schemes in order to optimise mitomycin administration during HIPEC.
KeywordsBody Surface Area Mitomycin Haematological Toxicity Plasma Exposure Population Pharmacokinetic Model
The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this study.
- 5.Rietbroek RC. Hyperthermia in combination with chemotherapy: from laboratory bench to bedside [dissertation]. Amsterdam: University of Amsterdam, 1996Google Scholar
- 8.Fujimoto S, Shrestha RD, Kokobun M, et al. Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer. Reg Cancer Treat 1989; 2: 198–202Google Scholar
- 11.van Ruth S, Verwaal VJ, Hart AA, et al. Heat penetration in locally applied hyperthermia in the abdomen during intraoperative hyperthermic intraperitoneal chemotherapy. Anti-cancer Research 2003; 23(2B): 1501–8Google Scholar
- 12.Beal SL, Sheiner LB. NONNEM user’s guide: NONNEM Project Group. San Francisco (CA): University of California, 1992Google Scholar
- 16.US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: population pharmacokinetics 1999 [online]. Available from URL: http://www.fda.gov/cber/gdlns/popharm.pdf [Accessed 2003 Nov 17]
- 17.Holford N. Wings for NONMEM. Available online from: http://wfn.sourceforge.net [accessed 2003 Nov 17]
- 18.National Cancer Institute, Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0, March 1998. Available from URL: http://ctep.cancer.gov/reporting/CTC-3.html [Accessed 2003 Nov 17]